Open AccessP720: PROACTIVE DASATINIB DOSE REDUCTION IN THE ALLG CML 12 DIRECT STUDY BASED ON TROUGH LEVELS MINIMISE TOXICITY AND PRESERVE EFFICACY
Author(s) -
Yeung D.,
Grigg A.,
Shanmuganathan N.,
Soltenbeck A.,
White D.,
Branford S.,
Viiala N.,
Rowlings P.,
Mills A.,
Shortt J.,
Tiley C.,
Ross D.,
Kipp D.,
Harrup R.,
Cunningham I.,
Kwan J.,
Eek R.,
Mutsando H.,
Tan K.S.,
Burbury K.,
Wright M.,
Hughes T.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000845764.61186.15
Subject(s) - dasatinib , cmin , medicine , clinical endpoint , toxicity , cumulative incidence , gastroenterology , oncology , clinical trial , cohort , myeloid leukemia , cmax , pharmacokinetics , imatinib